India-based global pharma company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL.
Brivaracetam is the bioequivalent to UCB Inc's Briviact Oral Solution, 10 mg/mL and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
Following the FDA approval, Lupin has commenced the launch of Brivaracetam Oral Solution in the United States.
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
Immedica Pharma gains European approval to extend Efmody use in adrenal insufficiency
Neurocrine agrees acquisition of Soleno Therapeutics
NeuroSense's PrimeC composition receives Brazilian patent
Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval
Abbisko Therapeutics' FGFR4 inhibitor irpagratinib granted orphan designation in Europe for HCC
US FDA approves i-Lumen Scientific's i-SIGHT2 clinical study for dry AMD
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share
ALK secures EU approval for EURneffy 1 mg as needle-free adrenaline option for children
Sanofi secures EU approval for Rezurock in chronic graft-versus-host disease
Boston Scientific receives FDA clearance for Asurys fluid management system
Aurinia Pharmaceuticals agrees to acquire Kezar Life Sciences
Rocket Pharmaceuticals secures FDA approval for Kresladi gene therapy in severe LAD-I
Pharming receives positive CHMP opinion for Joenja marketing authorisation